Suppr超能文献

T 细胞来源移植后淋巴组织增生性疾病的临床病理特征:单中心 9 例系列及 147 例报道病例的荟萃分析。

Clinicopathological characteristics of posttransplant lymphoproliferative disorders of T-cell origin: single-center series of nine cases and meta-analysis of 147 reported cases.

机构信息

KU Leuven, Translational Cell and Tissue Research , Leuven , Belgium.

出版信息

Leuk Lymphoma. 2013 Oct;54(10):2190-9. doi: 10.3109/10428194.2013.775436. Epub 2013 Mar 27.

Abstract

T-cell or natural killer (NK)-cell posttransplant lymphoproliferative disorder (T-PTLD) is a rare but severe complication after transplant. Here we present the clinicopathological features of a single-center series of nine cases. Additionally, we summarize the clinicopathological findings of 147 cases of T/NK-cell PTLD reported in the literature in an attempt to define subtype-specific characteristics. T/NK-cell PTLD occurs in patients of all ages, usually extranodally, and most frequently after kidney transplant. Organ specific incidence, however, is highest following heart transplant. Approximately one-third of T-cell PTLDs are Epstein-Barr virus (EBV)-related, with peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) being the most prevalent EBV-associated T-cell PTLD. A male predominance is observed, which is most striking in the EBV(+) group, particularly in PTCL, NOS. With a median posttransplant interval of 72 months, T-cell PTLDs are among the late-occurring PTLDs. Of the most common T-cell PTLDs, anaplastic large cell lymphoma (ALCL) has the best prognosis, whereas PTCL, NOS and hepatosplenic T-cell lymphoma (HSTCL) have the worst prognosis. EBV(+) cases seem to have a longer survival than EBV(-) cases, suggesting a different pathogenetic mechanism.

摘要

T 细胞或自然杀伤(NK)细胞移植后淋巴组织增生性疾病(T-PTLD)是移植后罕见但严重的并发症。在此,我们介绍了单中心 9 例病例的临床病理特征。此外,我们总结了文献中报道的 147 例 T/NK 细胞 PTLD 的临床病理发现,试图确定亚型特异性特征。T/NK 细胞 PTLD 可发生于所有年龄段的患者,通常为结外发病,最常发生于肾移植后。然而,心脏移植后器官特异性发病率最高。约三分之一的 T 细胞 PTLD 与 EBV 相关,其中最常见的 EBV 相关 T 细胞 PTLD 为未特指外周 T 细胞淋巴瘤(PTCL,NOS)。观察到男性发病居多,在 EBV(+)组中尤为明显,尤其是在 PTCL,NOS 中。T 细胞 PTLD 的中位移植后间隔为 72 个月,属于晚期发生的 PTLD 之一。在常见的 T 细胞 PTLD 中,间变性大细胞淋巴瘤(ALCL)的预后最好,而 PTCL,NOS 和肝脾 T 细胞淋巴瘤(HSTCL)的预后最差。EBV(+)病例的生存时间似乎长于 EBV(-)病例,提示存在不同的发病机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验